CX3CL1, a chemokine finely tuned to adhesion: critical roles of the stalk glycosylation and the membrane domain by Ostuni, Mariano, et al.
CX3CL1, a chemokine finely tuned to adhesion: critical
roles of the stalk glycosylation and the membrane
domain
Mariano Ostuni, Julie Guellec, Patricia Hermand, Pauline Durand,
Christophe Combadie`re, Fre´de´ric Pincet, Philippe Deterre
To cite this version:
Mariano Ostuni, Julie Guellec, Patricia Hermand, Pauline Durand, Christophe Combadie`re,
et al.. CX3CL1, a chemokine finely tuned to adhesion: critical roles of the stalk glyco-
sylation and the membrane domain. Biology Open, Royal Society, 2014, 3, pp.1173-1182.
<10.1242/bio.20149845>. <inserm-01095507>
HAL Id: inserm-01095507
http://www.hal.inserm.fr/inserm-01095507
Submitted on 15 Dec 2014
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

RESEARCH ARTICLE
CX3CL1, a chemokine finely tuned to adhesion: critical roles of the
stalk glycosylation and the membrane domain
Mariano A. Ostuni1,2,3,*, Julie Guellec1,2,3, Patricia Hermand1,2,3, Pauline Durand4, Christophe Combadie`re1,2,3,
Fre´de´ric Pincet4 and Philippe Deterre1,2,3,`
ABSTRACT
The multi-domain CX3CL1 transmembrane chemokine triggers
leukocyte adherence without rolling and migration by presenting
its chemokine domain (CD) to its receptor CX3CR1. Through the
combination of functional adhesion assays with structural analysis
using FRAP, we investigated the functional role of the other
domains of CX3CL1, i.e., its mucin stalk, transmembrane domain,
and cytosolic domain. Our results indicate that the CX3CL1
molecular structure is finely adapted to capture CX3CR1 in
circulating cells and that each domain has a specific purpose: the
mucin stalk is stiffened by its high glycosylation to present the CD
away from the membrane, the transmembrane domain generates
the permanent aggregation of an adequate amount of monomers to
guarantee adhesion and prevent rolling, and the cytosolic domain
ensures adhesive robustness by interacting with the cytoskeleton.
We propose a model in which quasi-immobile CX3CL1 bundles are
organized to quickly generate adhesive patches with sufficiently
high strength to capture CX3CR1+ leukocytes but with sufficiently
low strength to allow their patrolling behavior.
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INTRODUCTION
The migration of circulating leukocytes to injury sites is an early
step in the inflammation process and involves a sequence of
coordinated interactions between leukocytes and endothelial cells
(Luster et al., 2005; Langer and Chavakis, 2009). Chemokines,
which are a family of low-molecular-weight soluble proteins that
primarily attract leukocytes bearing the cognate receptors, are
central to this physiological and pathological event (Charo and
Ransohoff, 2006; Ransohoff, 2009). Chemokines trigger
leukocyte activation and their firm adhesion to the inflamed
endothelium, mainly through the mediation of integrins and their
cognate ligands (Combadie`re et al., 2007; Simon et al., 2009;
Speyer and Ward, 2011). Two of the members of the chemokine
family are exceptions: CXCL16 and CX3CL1. In addition to their
chemokine domain (called CD), these two chemokines possess
three other domains: a mucin-like stalk, a transmembrane (TM)
domain, and a cytosolic tail (Bazan et al., 1997; Matloubian et al.,
2000). When interacting with their cognate receptors (CXCR6
and CX3CR1, respectively), these chemokines induce cell-cell
adhesion (Ludwig and Weber, 2007). CXCL16 and CX3CL1 can
also be cleaved by metalloproteinases, such as ADAM10 and
ADAM17 (Garton et al., 2001; Hundhausen et al., 2003; Ludwig
et al., 2005), to yield a soluble form that is chemotactic.
The CX3CL1 molecule, with its unique CX3CR1 receptor
(Imai et al., 1997), is involved in adherence to the endothelium of
the inflammatory monocyte population (CD14hi CD162 CX3CR1+
CCR2+ in humans, Ly6Chi CX3CR1+ CCR2+ in mice) (Ancuta
et al., 2003; Geissmann et al., 2003; Tacke and Randolph, 2006)
likely through interaction with platelets (Schulz et al., 2007; Postea
et al., 2012). This chemokine has also been implicated in the
recruitment of NK lymphocytes (Guo et al., 2003; Lavergne et al.,
2003) and in neuronal survival (Meucci et al., 2000; Mizuno et al.,
2003; Cipriani et al., 2011; Kim et al., 2011). An additional
intriguing function of the CX3CR1-CX3CL1 pair is to regulate the
patrolling or ‘‘crawling’’ behavior of a minor monocytic
subpopulation called ‘‘resident’’ or ‘‘non-classical’’ monocytes
(CD14lo CD162+CX3CR1+ CCR22 in humans, Ly6Clo CX3CR1+
CCR22 in mice) in blood vessels (Auffray et al., 2007). We
recently showed that a monocytic subpopulation traffics and
adheres to the bone marrow in a CX3CR1-CX3CL1 dependent
manner (Jacquelin et al., 2013). For this patrolling behavior, the
adhesion must be fast to capture monocytes, strong enough to allow
sufficient time for screening the local environment, and small
enough to screen as much territory as possible. This entails a
precise adhesive potency, which is the subject of the present study,
and we show that each domain of the CX3CL1 molecule plays a
specific role in this adhesive behavior.
In the present paper, we show that CX3CL1, which is endowed
with only one TM domain, has a lateral diffusion that is slower
than that of the CX3CR1, which, similarly to all GPCRs, is a 7-
TM molecule, and we demonstrate that this slow diffusivity is due
to the glycosylation of the mucin stalk and the aggregation
generated by the TM domain. We also found that both of these
diffusion-limiting factors are highly required for the adhesiveness
of the chemokine. Our data indicate that glycosylation ensures the
accessibility of CX3CL1 to the CX3CR1 molecules buried in the
membrane of the counter-adhesive cell. Moreover, we show that
the only role of the CX3CL1 intracellular domain, which is
involved in CX3CL1 recycling (Liu et al., 2005), is to increase
the robustness of the adhesion. Our data allow the derivation of a
model in which the formation of adhesive patches is controlled by
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the dynamics of the CX3CR1 receptors that bind the CD domain
presented by a defined number of ligands prearranged in quasi-
immobile bundles. This model is consistent with the observed
patrolling behavior of CX3CR1-positive leukocytes.
RESULTS
The intracellular domain and the mucin stalk of CX3CL1 are
required for a strong adhesive potency
We first tested the contribution of different features of the
CX3CL1 molecule to its adhesiveness, i.e., the presence of its
cytosolic tail, the length of its mucin stalk, and its glycosylation.
To this end, we constructed three CX3CL1 mutated analogues:
one without the cytosolic tail (termed ‘‘w/o cyto CX3CL1’’), one
with half of the mucin stalk (termed ‘‘shCX3CL1’’), and one with
a fully deglycosylated stalk (termed ‘‘dgCX3CL1’’), which was
obtained by mutating the 52 serine or threonine residues of the
mucin stalk to alanine, i.e., all of the potential sites for O-
glycosylation. To follow the cellular expression of CX3CL1,
these molecules were linked to EYFP at the C terminus, whose
presence was indeed previously shown to not impair the function
of the whole protein (Liu et al., 2005; Hermand et al., 2008;
Huang et al., 2009). After expression in the COS7 cell line, the
molecular weight of the CX3CL1-EYFP chimera leveled at
120 kDa, i.e., the sum of the complete CX3CL1 (90 kDa) and of
the EYFP protein (30 kDa). Consistently, the w/o cyto CX3CL1
exhibited a molecular weight of 110 kDa, whereas the
shCX3CL1 mutant had a weight of approximately 70 kDa (i.e.,
the sum of the 40 kDa short CX3CL1 plus the EYFP protein).
The weight of the dgCX3CL1 mutant was 80 kDa, i.e., the sum of
the polypeptide of CX3CL1 (50 kDa) plus the EYFP protein
(Fig. 1A). The existence of some minor bands of lower molecular
weight as seen in the w/o cyto CX3CL1 well is probably due to
some intracellular forms of CX3CL1 that are not well processed
as previously analyzed in detail (Garton et al., 2001).
The adhesive potency of these mutated proteins was first tested
using the classical flow chamber assay (Fong et al., 1998; Haskell
et al., 2000; Daoudi et al., 2004; Hermand et al., 2008), in which
CX3CR1-positive CHO cells (CX3CR1+) were circulated at 1.5
dyne/cm2 over adherent COS7 cells expressing the CX3CL1-
EYFP chimera. The number of CX3CR1+ cells that adhered to
COS7 cells expressing the w/o cyto CX3CL1 was found to be
unchanged (if not higher) compared to those adhering to the
COS7 cells expressing the CX3CL1 native molecule (Fig. 1B). In
contrast, the number of CX3CR1+ cells adhering to COS7 cells
expressing shCX3CL1 or dgCX3CL1 was 2-fold and 4-fold
lower, respectively (Fig. 1B). Moreover, we used confocal
microscopy to confirm that the three CX3CL1 variants were
well expressed at the COS7 external membrane (Fig. 1C) and that
the proportion of the membrane-targeted proteins to the whole
expression was similar for the four constructs (Fig. 1D).
The adhesive potency of the CX3CL1 variants was also tested
through a dual pipette assay giving access to the force required to
dissociate a cell doublet (Daoudi et al., 2004). We found that cells
expressing the w/o cyto CX3CL1 displayed only a 4-nN
dissociation force toward cells expressing the CX3CR1
receptor, whereas the native molecule developed a 5-nN force
(Fig. 1E) for a similar number of positive adhesive events
(Fig. 1F). The dissociation force of both the shCX3CL1 and
dgCX3CL1 variants was also significantly reduced (Fig. 1E), and
the probability of forming adhesive doublets was 40% decreased
compared with the native CX3CL1 (Fig. 1F). We previously
showed using a BRET assay that the native CX3CL1 molecule
forms aggregates (Hermand et al., 2008): we then verified here
that dgCX3CL1 showed a BRET at an amplitude similar that of
native CX3CL1 (supplementary material Fig. S1).
Taken together, these data show that the shortening of the
mucin stalk of CX3CL1 and the mutation of the potentially
glycosylated residues of the mucin stalk are both deleterious for
the adhesive potency of the chemokine to a larger extent than the
absence of the cytosolic domain. To understand at the molecular
Fig. 1. Adhesive potency of the truncated and deglycosylated CX3CL1
mutants compared to native CX3CL1. (A) Immunoblotting of the different
CX3CL1-EYFP chimeras expressed in the COS7 cell line with anti-
CX3CL1 mAb. Thirty micrograms of membrane lysates from COS7 cells
expressing CX3CL1 chimeras were loaded on a 10% polyacrylamide gel
under reducing conditions, transferred to a nitrocellulose membrane, and
incubated overnight at 4˚C under agitation with anti-human CX3CL1 primary
antibody. The immune complexes were visualized with secondary
peroxidase-conjugated antibodies using a chemiluminescent kit. (B) Number
of CX3CR1+ CHO cells adhering to a monolayer of COS7 cells expressing
various forms of CX3CL1-EYFP chimera. The results were obtained using
a flow adherence assay. ** p,0.01 and *** p,0.001 compared with native
CX3CL1-EYFP. (C) Membrane localization of CX3CL1 and its variants.
Representative images of COS7 cells expressing EYFP chimeras of
CX3CL1, CX3CL1 w/o cyt, shCX3CL1, or dgCX3CL1. The images were
taken with a Leica SP5 confocal microscope (636 dry objective). The bars
represent 10 mm. (D) The membrane expression of the various constructs
was evaluated by confocal microscopy as a ratio of membrane to total
fluorescence. (E) Dissociation force, assessed by the two pipette assay,
between CX3CR1+ CHO-cells and COS7 cells expressing the indicated
CX3CL1-EYFP chimera. (F) Percentage of positive adherent cell doublets
calculated for each CX3CL1-EYFP chimera. * p,0.05 and ** p,0.01
compared with native CX3CL1-EYFP.
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level the reasons underlying this decreased adhesion, we tested
three possible causes: lesser accessibility of the CD, change in the
supramolecular organization via the cytoskeleton, and impairment
of CX3CL1 lateral diffusion.
The mucin stalk is maintained extended by glycosylation to
present the CD to the receptor
COS7 cells transiently transfected with the three different
CX3CL1-EYFP chimeras and labeled with anti-CX3CL1-PE
antibody were analyzed by FACS. All of the chimera
constructions gave similar EYFP signals (Fig. 2, grey bars) and
were similarly targeted at the external membrane (Fig. 1C,D).
However, dgCX3CL1 showed a marked decrease in staining by the
anti-CX3CL1-PE antibody (Fig. 2, empty bars), indicating that the
antibody accessibility was lowered. These results, together with the
flow adhesion results, strongly suggest that the accessibility of the
CD to both antibody (Fig. 2) and CX3CR1 (Figs 1 and 2) is
compromised when the chemokine is deglycosylated.
The adhesion and FACS measurements (Figs 1 and 2) with
shCX3CL1 also support this interpretation. A shorter mucin stalk
presents the CD outside the membrane in such a way that it is
accessible to a free molecule in solution, such as an antibody
(Fig. 2). However, because it remains closer to the membrane, it
is less likely to encounter a transmembrane protein from another
cell, such as CX3CR1. This reasoning explains why the
probability of adhesion (flow chamber and dual pipette assay)
is reduced (Fig. 1B). The decrease in adhesion strength (Fig. 1E)
obtained in the dual pipette assay was also likely due to a lesser
number of CX3CR1-CX3CL1 bonds.
The cytosolic domain ensures the robustness of the
adhesion via the cytoskeleton
The data obtained with the w/o cyto CX3CL1 mutant using the dual
pipette assay suggest that the CX3CL1 molecule without its
cytosolic domain has the same probability to functionally bind the
CX3CR1 receptor in the counter-adhesive cell as the native
CX3CL1 (Fig. 1F), but that its resistance to radial force is slightly
less, likely due to some impaired link to the cytoskeleton (Fig. 1E).
Among the components of the cytoskeleton, we specifically
explored the potential role of the actin network. We found that
treatment with latrunculin B, which inhibits actin polymerization
(Wakatsuki et al., 2001), leads to a 25% decrease in the dissociation
force (supplementary material Fig. S2), i.e., the level obtained in the
absence of the cytosolic tail. Thus, it is conceivable that a
connection between CX3CL1 and the actin cytoskeleton is
required to ensure robust adhesion. However, this potential
connection appears dispensable to the capture of adhering cells in
the flow assay (Fig. 1B) likely because the force displayed by w/o
cyto CX3CL1 is sufficient to resist the flow rate used in our assay.
The lateral diffusion of CX3CL1 is slower than that of CX3CR1
Since the lateral diffusion of an adhesion molecule is crucial for
its adhesive function (Dustin and Springer, 1991; Kucik et al.,
1996; Kusumi et al., 1999; Kucik et al., 2001; Yu et al., 2010), we
investigated the membrane diffusion of CX3CL1 and CX3CR1
through the FRAP technique.
We first transiently transfected the EYFP chimera into COS7
cells and found that the mobile fraction of both CX3CL1 and
CX3CR1 represented approximately half of the whole membrane
population (Tables 1 and 2) and that the time of recovery after
bleaching of a 5-mm-diameter spot was clearly longer for the
mobile fraction of CX3CL1 (Fig. 3A, full squares, t1/25
31.562.79 s) than for CX3CR1 (Fig. 3A, empty squares, t1/25
13.560.73 s). This recovery was most likely due to actual lateral
diffusion because we found that the characteristic time of diffusion
was directly proportional to the surface of the bleached area
(Fig. 3B), confirming that the fluorescence recovery was not due to
the potential arrival of cytosolic CX3CL1 in the bleached
membrane area. In addition, this experiment showed that, at
least in the distance range of 3–5 mm, CX3CL1 and CX3CR1
displayed Brownian motion without constraints, i.e., neither
‘‘microdomains’’ nor ‘‘fences’’ (He and Marguet, 2008). We
further ensured that the slow diffusion of the CX3CL1-EYFP
chimera is not due to the overexpression of the protein (Fig. 3C):
the same diffusion rate was found with a CX3CL1 expression level
that was 2- to 10-fold (Fig. 3C, empty squares) lower than that
currently obtained (Fig. 3C, filled square).
The data obtained with the COS7 cell line indicate that the
diffusion rate of CX3CL1 is approximately 361022 mm2 s21
(Fig. 3D, grey bars), whereas that of CX3CR1 in the same cell
type is approximately 861022 mm2 s21 (Fig. 3D, empty bars).
We then assessed whether the low rate of CX3CL1 lateral
diffusion is also found in other cell types. In CHOldlD, HEK293,
and L929 cells (murine fibroblastic origin) (Fig. 3D; Table 1),
Fig. 2. Analysis of the truncated and deglycosylated CX3CL1-EYFP
chimera by immunostaining. Flow cytometry signal from different CX3CL1-
EYFP chimera revealed by EYFP fluorescence (filled bars) or by anti-
CX3CL1 PE-conjugated antibody (empty bars). *** p,0.001 compared with
native CX3CL1-EYFP.
Table 1. Characteristics of the lateral diffusion rate of CX3CL1 in various cell types detected using EYFP chimera or antibody staining
Cell type COS7 COS7 HEK293 CHOldlD L929 Activated HUVEC
Transfection and
fluorescent staining
Transient
CX3CL1-EYFP
Transient CX3CL1
FITC-mAb
Stable CX3CL1-
EYFP
Transient
CX3CL1-EYFP
Stable CX3CL1-
EYFP
FITC-mAb
D (mm2 s21) 0.02860.003 0.06160.006 0.04860.003 0.05060.006 0.03160.013 0.08460.011
Mobile fraction (%) 51.364.4 53.566.8 45.063.5 45.668.5 27.863.5 66.164.1
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the diffusion rate of the CX3CL1-EYFP chimera in the cell
surface was between 3 and 561022 mm2 s21, i.e., within a similar
range as in COS7 cells. Furthermore, we verified that the
bleaching mode had no influence on the diffusion rate data. Using
the mild bleaching mode with a fringe pattern (Fluorescence
Recovery After Photobleaching Pattern, FRAPP) (Davoust et al.,
1982; Binks et al., 1989; Gambin et al., 2006), we found that
CX3CL1 and CX3CR1 displayed a diffusion rate in HEK293
cells similar to that obtained using classical FRAP
(supplementary material Table S1). We also confirmed that this
diffusion was indeed lateral diffusion because the same results
were obtained when the fluorescence is monitored in the TIRF
mode (supplementary material Table S1). The analysis of the data
obtained using this technique showed that the fluorescence
recovery of CX3CL1 was purely exponential, indicating that the
diffusive objects are essentially monodisperse in size
(supplementary material Fig. S3).
We then used FRAP to analyze the diffusion of CX3CL1 in
primary cells. To this end, we stained the chemokine with
fluorescent antibodies and found that the diffusion of CX3CL1 in
activated primary HUVEC cells was similar to that obtained with
COS7 cells transfected with CX3CL1 (Table 1). Furthermore,
CX3CL1 expressed by activated HUVEC cells also diffused in a
Brownian mode (Fig. 3B). The chemokine stained with mAb was
surprisingly found to be faster (861022 mm2 s21) than the EYFP-
chimera (Table 1). This is probably due to some slight restriction
of lateral diffusion due to the addition of the intracellular EYFP
moiety, which could slow down the whole molecule by
interacting with some intracellular component. Because
CX3CR1 is primarily expressed in circulating monocytes, we
measured its diffusion rate in the monocytic cell line THP-1 and
found a diffusion rate of approximately 961022 mm2 s21
(Table 2). We concluded that the CX3CR1, which, as a GPCR,
possesses 7 TM domains and is likely found as a dimer
(Darbandi-Tehrani et al., 2010), is always more diffusive than
its ligand CX3CL1, which is endowed with only one TM domain.
Glycosylation of the mucin stalk is responsible for the slow
CX3CL1 diffusivity
We also assayed the effect of the deletion of the different parts of
CX3CL1 on its diffusion rate in the COS7 cell line (Fig. 4A). The
truncation of the CD (‘‘w/o CD CX3CL1’’) had no effect on the
lateral diffusion of the molecule, whereas the truncation of the
cytosolic tail (‘‘w/o cyto CX3CL1’’) resulted only in a modest
1.2-fold increase in the diffusion rate. In contrast, the truncation
of the extracellular region (‘‘cyto-TM’’) yielded a net 2-fold
increase. Moreover, the truncation of both the intracellular and
extracellular regions of CX3CL1 without changing the TM
domain resulted in a molecule that was almost 3-fold more
mobile than the whole molecule. Thus, it appears that the
extracellular part of the chemokine is largely involved in the
restraining of its diffusion rate.
To assess the impact of glycosylation on the lateral diffusion of
CX3CL1, we used FRAP to test the diffusion of the dgCX3CL1
variant and found that its diffusion rate was more than 2-fold
larger than that of native CX3CL1 (Fig. 4A). To confirm that this
dramatic increase in the diffusion rate is truly due to the absence
of glycosylation, we performed experiments with the
glycosylation-defective CHO cell line, termed CHOldlD
(Krieger et al., 1981) (Fig. 4B). When these cells were
deprived of glycosylation substrates (i.e., with 0.1% SVF), the
expressed CX3CL1 was indeed of a lower molecular weight
(80 kDa instead of 130 kDa, supplementary material Fig. 4C) and
diffused at a 2-fold higher rate (Fig. 4B, left grey bar). In
addition, the diffusion rate of the dgCX3CL1 chimera and the TM
Table 2. Characteristics of the lateral diffusion rate of CX3CR1 in various cell types and detected using EYFP chimera or
antibody staining
Cell type COS7 HEK293 CHOldlD CHO Monocytic THP-1
Transfection and fluorescent
staining
Transient CX3CR1-
EYFP
Stable CX3CR1-
EYFP
Transient CX3CR1-
EYFP
Stable CX3CR1 PE-
mAb
FITC-mAb
D (mm2 s21) 0.08260.003 0.07760.001 0.08360.010 0.14060.015 0.08960.022
Mobile fraction (%) 45.162.2 48.563.9 47.665.6 38.161.2 51.2
Fig. 3. Analysis of the lateral diffusion of CX3CL1 and CX3CR1 in
various cell types. (A) Kinetics of the fluorescence recovery after
photobleaching of a 5-mm-diameter bleached area at the surface of COS7
cells expressing CX3CL1-EYFP (filled squares) or CX3CR1-EYFP (empty
squares) chimeras. (B) Dependence as a function of the surface of the
bleached area of the FRAP characteristic time of CX3CL1 expressed in
COS7 cells either as an EYFP chimera (filled squares) or bound to FITC-
stained specific antibody (empty squares), of FITC-Ab bound CX3CL1 in
HUVEC cells (filled circles), and of CX3CR1-EYFP expressed in COS cells
(filled triangles). (C) The diffusion rate of CX3CL1-EYFP was measured at
the surface of COS7 cells expressing different CX3CL1-EYFP levels as the
membrane fluorescence level measured by confocal microscopy. The black
square represents the data obtained using COS7 transfected under the
conditions that were classically used throughout this study. (D) The diffusion
rates of CX3CL1-EYFP (filled bars) and of CX3CR1-EYFP (empty bars) were
measured in different cell lines as indicated.
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moieties remained unchanged (Fig. 4B), showing that the
conditions that lead to a total absence of cell glycosylation did
not influence the lateral diffusion of the control membrane
proteins. Thus, it appears that the glycosylation of the mucin stalk
of CX3CL1 improves the adhesion potency of CX3CL1 by
ensuring the accessibility of the CD (Figs 1 and 2) but induces a
decreased diffusion rate (Fig. 4A,B), which was a priori contrary
to what would be expected for optimized adhesion.
Monodisperse CX3CL1 bundles are induced by the
transmembrane domain
The diffusion rates of the dgCX3CL1 variant, the TM variant, and
CX3CL1 in the glycosylation-defective CHOldlD cells (0.08–
0.012 mm2 s21) (Fig. 4A,B) appeared slow for a protein with a
single transmembrane domain because it was of the same order as
that of CX3CR1 (Fig. 3D). This slow diffusion could not be due to
glycosylation. We previously showed that CX3CL1 is aggregated
and that this aggregation – as assessed by BRET/FRET experiments
– is mainly controlled by its TM domain (Hermand et al., 2008). We
notably showed that the replacements of the 321–325 residues or of
the 326–332 residues by ALA (giving the mutants termed CX3CL1-
ALA5 and CX3CL1-ALA7, respectively) had no impact on the
aggregation (Hermand et al., 2008). Consistently, these mutations
had no effect on the diffusion rate of the molecule (Fig. 4D). When
all of the 321–332 residues were replaced by ALA, the resulting
CX3CL1 (termed ‘‘CX3CL1-ALA12’’) was previously found to be
neither aggregated nor glycosylated (Hermand et al., 2008).
Consistently, we found that the CX3CL1-ALA12 diffusion rate
(0.13 mm2 s21, Fig. 4D) was two-fold higher than the diffusion rate
of dgCX3CL1 (0.07 mm2 s21; Fig. 4A), confirming that the slow
diffusion of deglycosylated CX3CL1 is due to aggregation. Hence,
we concluded that CX3CL1 is presented as a monodisperse bundle
(supplementary material Fig. S3) on the surface of cells and that its
packing is driven by its transmembrane domain.
DISCUSSION
The adhering chemokine CX3CL1 is natively expressed as a
transmembrane molecule consisting of four domains. The CD (76
residues) – a globular protein domain 3 nm in diameter
maintained by two disulfide bridges – is structurally similar to
that of other secreted chemokines. The mucin stalk (241 residues)
is 26 nm in length (Fong et al., 2000) and highly glycosylated
with 17 mucin-like repeats (Imai et al., 1997; Fong et al., 1998).
The transmembrane domain is involved in the aggregation of the
molecule, as assayed by BRET and FRET (Hermand et al., 2008).
Finally, the cytosolic domain (C-terminus) is involved in the
cellular trafficking of CX3CL1 (Andrzejewski et al., 2010) and in
its constitutive endocytosis (Liu et al., 2005; Huang et al., 2009).
Using numerous CX3CL1 mutants whose characteristics are
summarized in Table 3, our present study provides important
clues that aid our understanding of the specific roles of each
domain of the CX3CL1 molecule in its adhesive function
(Fig. 5).
1. As previously underlined, the CD is the only region of
CX3CL1 that binds to the receptor (Fong et al., 1998; Mizoue
et al., 2001). Its high affinity (Kd of approximately 0.1–1 nM)
provides the actual adhesion energy, particularly due to its very
low off-rate compared to that of any other chemokine/chemokine
receptor pair (Haskell et al., 2000). However, it was recognized
that this favorable affinity cannot solely account for the
exceptional bond strength afforded by the CX3CL1-CX3CR1
pair when the CX3CL1 molecules are isolated (Lee et al., 2004).
2. Our data provide several lines of evidence supporting the
hypothesis that the glycosylated mucin stalk plays an important
role in the presentation of the CD to the outer medium. It was
previously demonstrated that the presence of the mucin stalk
increases the power of the adhesive CX3CL1-CX3CR1
interaction (Fong et al., 2000). The same researchers showed
that the E-selectin stalk can replace the mucin domain of
CX3CL1 without changing its adhesion potency and proposed
that the mucin stalk function is limited to the extension of the
Fig. 4. Lateral diffusion rate of CX3CL1-EYFP and its truncated,
deglycosylated, or TM mutants. (A) Diffusion rate assessed by FRAP in
COS7 cells of native CX3CL1-EYFP or CX3CL1-EYFP lacking its chemokine
domain (named ‘‘w/o CD CX3CL1’’), its cytosolic tail (named ‘‘w/o cyto
CX3CL1’’), its extracellular part (named ‘‘cyto-TM’’), or both of its extracellular
and intracellular regions (named ‘‘TM’’) or deglycosylated (named
‘‘dgCX3CL1’’); * p,0.05 and *** p,0.001 compared with native CX3CL1-
EYFP. (B) Diffusion rate of CX3CL1-EYFP and various mutants as assessed
by FRAP in CHOldlD cells cultured either with 10% FCS (empty bars) or 0.1%
FCS (filled bars) medium. *** p,0.001 compared with the respective 10%FCS
cultured CX3CL1-EYFP-expressing cells. (C) Immunoblotting of CX3CL1
chimera in CHOldlD. Thirty micrograms of membrane lysates from CHOldlD
transfected with CX3CL1-EYFP and cultivated under normal (right) or
deprived (left) serum conditions were loaded onto a 10% polyacrylamide gel
under reducing conditions, transferred to a nitrocellulose membrane, and
incubated overnight at 4˚C under agitation with anti-human CX3CL1 primary
antibody. The immune complexes were visualized with secondary peroxidase-
conjugated antibodies using a chemiluminescent kit. (D) Lateral diffusion
measured by FRAP in COS7 cells expressing the native CX3CL1-EYFP
chimera or different constructions in which residues 321 to 325 were mutated
to ALA (named ‘‘CX3CL1-5ALA’’), residues 326 to 332 were mutated to ALA
(‘‘CX3CL1-7ALA’’), or residues 321 to 332 were mutated to ALA (‘‘CX3CL1-
12ALA’’). The lateral diffusion of CX3CL1-12ALA and of this mutated
chemokine without its extracellular domain (‘‘cyto-TM-12ALA’’) or without its
extra and intracellular domains (‘‘TM-12ALA’’) is also reported. *** p,0.001
compared with native CX3CL1-EYFP.
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chemokine domain away from the endothelial cell surface to
present it to flowing leukocytes (Fong et al., 2000). However, the
exact role of the glycosylation of the mucin stalk of CX3CL1 was
not analyzed. In this study, we demonstrate that the length and the
glycosylation state of the stalk domain are directly involved in the
adhesive properties of CX3CL1. Two CX3CL1 mutants (see
Table 3) presenting either a shorter glycosylated stalk domain or
a normal-length but fully deglycosylated stalk domain exhibit a
strongly diminished or abolished adhesion ability under flow
conditions (Fig. 1B) and under pulling by the dual pipette assay
(Fig. 1E). We believed that the reduced adhesion is due to the
limited accessibility to the receptor of the CD that is more buried
in the glycocalyx. In the case of the shCX3CL1, it is because it
cannot extend beyond the glycocalyx. Regarding the dgCX3CL1,
the absence of glycosylation reduces the stiffness of the mucin
stalk which ends up being not fully extended, explaining why the
CD in the dgCX3CL1 variant has less access to its molecular
partners, i.e., either the cognate antibody (Fig. 2) or the CX3CR1
receptor, as assessed by the lower probability of adhesion events
(Fig. 1E). We cannot formally exclude that the possibility that the
mutations of all glycosylation sites in the mucin stalk could
generate other structural changes; however our data show that the
dgCX3CL1 is targeted to the plasma membrane as well as the
native CX3CL1 (Fig. 1C,D) and has the same aggregation status
(supplementary material Fig. S1). To bear out that the CD is in a
similar conformation in both dgCX3CL1 and native CX3CL1
molecules, we compared its accessibility to specific antibody
when the glycocalyx is absent, i.e. in CHOldlD cells in 0.1% SVF
condition (supplementary material Fig. S4). We found that the
dgCX3CL1 is similarly targeted to the membrane (supplementary
material Fig. S4A) and get similar access to the antibody (PE-
stained) (supplementary material Fig. S4B). Taken together, our
data show that the glycosylation of the CX3CL1 mucin domain is
crucial for its stretch out of the profound layer of glycocalyx and
for allowing the chemokine domain to obtain access to the
receptor on the counter cell, as shown for P-selectin (Patel et al.,
1995) and Natural Killer cell receptor NKp30 (Hartmann et al.,
2012). This extended CX3CL1 may also allow better interactions
with CX3CR1 because a greater intermembrane distance
minimizes the repulsive forces between the glycocalyces.
3. As reported for the VSV-G-protein (Scullion et al., 1987)
and class I MHC glycoprotein (Wier and Edidin, 1988), we found
that the CX3CL1 glycosylation markedly restrains its lateral
diffusion, as determined using a deglycosylated CX3CL1 mutant
(dgCX3CL1, Fig. 4A) and CX3CL1 expression in the CHOldlD
cell line, which is unable to glycosylate under serum-deprived
conditions (Fig. 4B).
4. Our study also provides evidence that the transmembrane
domain, in addition to anchoring the protein to the membrane,
aggregates itself to form a bundle with several CX3CL1. This
phenomenon is exemplified by the dramatic difference between
the lateral diffusion of the two deglycosylated CX3CL1 variants
(see Table 3): the diffusion of CX3CL1-12ALA, which was
Table 3. Summary of the data collected about CX3CL1 and its mutants
CX3CL1 CX3CL1-EYFP
dgCX3CL1-
EYFP
CX3CL1-EYFP
in deprived
CHOldlD
w/o cyto –
CX3CL1-EYFP
shCX3CL1-
EYFP
5ALA/7ALA-
CX3CL1-EYFP
12ALA-CX3CL1-
EYFP
Mr (kDa) (Fig. 1A) 90 120 80 80 110 70 130
a 80a
Glycosylation of the
mucin stalk
YES YES NO NO YES YES YESa NOa
Expression at the
external membrane
YES YES
(Fig. 1C,D)
YES (Fig. 1C,D ND YES (Fig. 1C,D YES (Fig. 1C,D YESa lowa
Accessibility to Ab YES YES (Fig. 2) low (Fig. 2) YES (Fig. 2) YES (Fig. 2) ND ND
Adhesive potency
(flow adhesion)
+++ +++ (Fig. 1B) + (Fig. 1B) +++ (Fig. 1B) ++ (Fig. 1B) +++a 0a
Adhesive potency
(2-pipettes assay)
+++ +++ (Fig. 1E) + (Fig. 1E) ++ (Fig. 1E) ++ (Fig. 1E) +++a 0a
BRET/FRET YESa YESa (Fig. S1) YES (Fig. S1) ND ND YESa NOa
D (cm2/sec) (Fig. 4) 0.028 0.074 0.036 0.038 0.023/0.028 0.130
aData from Hermand et al. 2008
Fig. 5. Scheme illustrating the physiological functions of the
different CX3CL1 structural domains. The CX3CL1 molecule is
quasi-immobile due to the high glycosylation of its mucin stalk and the
multimerization driven by its TM domain. The oligomer molecule is catching
mobile CX3CR1 receptors through binding to its CD (chemokine domain)
thanks to the flexible and stretched mucin stalk. The robustness of the
adhesion is ensured by the CX3CL1 cytosolic domain anchoring it to
the cytoskeleton.
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previously shown to be disaggregated (Hermand et al., 2008)
(0.13060.004 mm2 s21, Fig. 4D), is noticeably greater than that
of dgCX3CL1 (0.07460.001 mm2 s21, Fig. 4A), which displays
the same positive BRET as natural CX3CL1 (supplementary
material Fig. S1). Moreover, we found that the diffusion of the
TM of the CX3CL1-12ALA mutant (0.17760.006 mm2 s21,
Fig. 4D) is more than 2-fold faster than that of the TM of natural
CX3CL1 (0.08160.001 mm2 s21, Fig. 4A).
It should be noticed that the BRET data indicate the
aggregation status of the CX3CL1 molecule (Hermand et al.,
2008) but do not provide any clues regarding the fraction of
aggregated molecules or the degree of aggregation. From our
FRAP data (Figs 3 and 4), we can infer that this aggregation
involves the great majority of the molecules, that it is unchanged
even in cells with a low number of expressed CX3CL1 (Fig. 3B)
and that the aggregation appears to be relatively homogeneous
because the population of mobile CX3CL1 appears to be
‘‘monodisperse’’ (supplementary material Fig. S3). However,
more work is required to precisely determine the number of
monomers in each CX3CL1 aggregate, even though our data
argue that a fixed number of monomers are found in each
CX3CL1 bundle, giving rise to a fixed adhesive strength. Finally,
our work notes that this aggregation with a fixed number of
elements is likely an intrinsic multimerization because it occurs in
many cell type environments (Fig. 3 and Table 1).
5. Our data indicate that the cytosolic domain ensures the
robustness of the adhesion, probably by anchoring the bundle to
some intracellular structures as cytoskeleton. The role of this
domain is clearly visible using the dual pipette assay (Fig. 2) and
could be due to the interaction of the CX3CL1 cytosolic tail with
the actin network, as previously shown for E-cadherin/catenins
and integrins adhesion (van Kooyk and Figdor, 2000; Noda et al.,
2010). This is also consistent with the decreased adhesion
observed in our experiment using latrunculin B (supplementary
material Fig. S2). More work is still needed to assert this link. In
any case, the truncation of this tail does not affect flow adhesion
under our shear stress conditions (Fig. 1B). This indicates that the
main resistance to pulling the cell expressing CX3CL1 from the
one expressing CX3CR1 comes from the whole CX3CL1
molecule structure and only in a minor part from its links to
intracellular partners. This result is in accordance with previous
results that demonstrates that the intracellular domain of murine
CX3CL1 is not involved in static adhesion (Andrzejewski et al.,
2010). This contribution of the cytosolic tail to the adhesive
potency of CX3CL1 adds to its role in the recycling of the
chemokine by binding to dynamin in order to facilitate
constitutive endocytosis (Huang et al., 2009).
Overall, the findings suggest a structural model of the CX3CL1
molecule that appears finely adapted to its adhesive function
(Fig. 5): several CX3CL1 molecules with CDs that are perfectly
accessible are presented together to circulating leukocytes, and
their subsequent adhesion will be robust. The slow diffusion of
CX3CL1 may appear to be unfavorable for adhesion. However,
because several CX3CL1 molecules are presented together, there
is likely no need to bring more CDs to the adhesion area. It is
even possible that this slow diffusion guarantees the involvement
of a relatively accurate and constant number of CDs, making the
initial adhesion more reproducible. The diffusion of CX3CR1
molecules that have to migrate toward the CX3CL1 bundle will
control the dynamics of adhesion patch formation. Thus, the
comparison of the CX3CL1-CX3CR1 pair to the integrin-integrin
ligand couple revealed that it is the receptor rather than the
chemokine that behaves as an integrin: its diffusion and its
aggregation are directly involved in its interaction with the
protruded immobile and multivalent ligand to form an adhesive
complex.
CX3CL1 is a special adhesive chemokine that is able to
develop a strong specific interaction with its receptor CX3CR1
and is able to catch a circulating monocyte without a rolling step
(Haskell et al., 1999). However, this adhesive potency remains
lower than that of integrin (Kerfoot et al., 2003). The CX3CL1-
CX3CR1 pair also allows the patrolling or ‘‘crawling’’ behavior
of the CX3CR1-positive monocytes in the lumen of blood vessels
(Auffray et al., 2007) and within the bone marrow (Jacquelin
et al., 2013). All of these in vivo functions require a finely tuned
adhesive potency that perfectly matches the model detailed in the
present structural study. For instance, the presentation of
CX3CL1 as quasi-immobile bundles has advantages that can
explain the patrolling role of the CX3CL1-CX3CL1 pair. To
ensure strong binding, the initial CX3CR1-CX3CL1 bond must
be followed by the formation of more bonds before it breaks. The
lifetime of a single bond is roughly given by t0exp(2DG/kBT),
where the prefactor t0 is ,1028 s for molecules of this size
(Evans, 2001), kBT is the thermal energy, and DG is the energy of
the bond. For Kd51 nM, DG520 kBT, which results in a lifetime
of approximately 5 s. Because the diameter of a monocyte is 8–
14 mm (Geissmann et al., 2003; Tacke and Randolph, 2006) and
assuming that 26104 CX3CR1 molecules are found per monocyte
(Moatti et al., 2001), the average surface per receptor is
approximately 0.002–0.01 mm2/CX3CR1. Hence, considering
the diffusion coefficient of CX3CR1 (0.1 mm2/s), a second
bond will form within 0.1 s, i.e., before the first bond dissociates.
This finding strongly suggests that because several CX3CL1
molecules are presented together at the same location, the
formation of the first bond induces all of the other CX3CL1
molecules of the bundle to be bound to CX3CR1 partners. This
process guarantees a strong binding of the monocytes and prevents
rolling. However, monocytes must not be permanently attached.
Therefore, the total number of CX3CR1-CX3CL1 bonds must
remain limited to avoid irreversible adhesion. The slow diffusion
of CX3CL1 (either immobile or 10-fold slower than that of
CX3CR1) is also an advantage because it likely prevents the
formation of too many bonds, thereby making the adhesion
reversible and allowing specific functions, such as patrolling.
MATERIALS AND METHODS
CX3CL1 constructs
The cx3cl1 constructs in pcDNA3 (Invitrogen), pEYFP-N1 (Clontech),
and pRluc-N2 (Perkin-Elmer) were obtained through PCR amplification
using cx3cl1-pBLAST (Invivogen Cayla, Toulouse, France) as the
template and primers containing a HindIII restriction site in the 5-
position and a BamHI restriction site in the 3-position, as described
previously (Hermand et al., 2008). The HindIII/BamHI fragment was
then cloned into the different plasmids. The truncated and mutated
constructs were generated using the QuikChange II site-directed
mutagenesis kit according to the manufacturer’s instructions
(Stratagene). Briefly, 20 ng of the various plasmid constructs was used
as the template with mutated nucleotide primers, as described previously
(Hermand et al., 2008). The PCR conditions were as follows:
predenaturing at 95 C˚ for 1 min followed by 18 cycles of denaturing at
95 C˚ for 50 s, annealing at 60 C˚ for 50 s, and extension at 68 C˚ for
1 min/kb. After digestion with DpnI, 2 ml of the PCR product was used to
transform the XL10-Gold ultracompetent cells provided with the kit. The
appropriate clones were identified by sequencing.
The oligonucleotide primers used for the mutagenesis of human
CX3CL1 are the following. To generate the CX3CL1 without the
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cytosolic domain from CX3CL1 (w/o cyto CX3CL1), we used 59-GTGG-
CCATGTTCACCTACGGGGGAGGGGATCCACCG-39 and 59-CGGT-
GGATCCCCTCCCCCGTAGGTGAACATGGCCAC-39. To generate
the short CX3CL1 (shCX3CL1) from CX3CL1, we used 59-CCACTGC-
CGCCACGTGGCAGGTGGGGCTGCTGGCCTTCC-39 and 59-GGAA-
GGCCAGCAGCCCCACCTGCCACGTGGCGGCAGTGG-39. To generate
the deglycosylated CX3CL1 (dgCX3CL1), we used a synthetic gene from
GeneArt (Life Technologies, Saint-Aubin, France). The CX3CL1
constructs without the CD (w/o CD CX3CL1), without the mucin stalk
(cyto-TM), and with only the transmembrane domain (TM) were
performed as previously described (Hermand et al., 2008).
Cell culture and transfection
A human embryonic kidney cell line (HEK293), a fibroblast-like cell line
derived from monkey kidney tissue (COS7), and the Chinese Hamster
Ovary cell line (CHO) were grown in DMEM medium supplemented
with 10% fetal calf serum (FCS), 1% sodium pyruvate, and antibiotics.
The monocytic cell line THP-1 was grown in RPMI medium
supplemented with 10% fetal calf serum (FCS), 1% sodium pyruvate,
and antibiotics. UDP-Gal/UDP-GalNAc 4-epimerase5deficient mutant
Chinese Hamster Ovary (CHO) cells denoted CHOldlD (Kingsley et al.,
1986) were grown in Ham F-12 medium supplemented with 10% or 0.1%
FCS and antibiotics. The 4-epimerase deficiency prevents the synthesis
of UDP-Gal and UDP-GalNAc under normal culture conditions when
glucose is the sole sugar source. Transient or stable transfections were
performed using JetPei (PolyPlus Transfection, Illkrich, France)
according to the manufacturer’s instructions. Stably transfected cells
were selected with 1 mg/ml geneticin (G418, Life Technologies), and
single clones were established by limited dilution. Human umbilical vein
endothelial cells (HUVEC) were purchased from Lonza (Basel,
Switzerland) and cultured in EBM-2 medium (Lonza) following the
manufacturer’s instructions. The cells were subcultured before reaching
confluence for a maximum of three passages. CX3CL1 expression was
induced by the addition of IFN-c and TNF-a (500 units/ml and 20 ng/ml,
respectively), as previously described (Hermand et al., 2008).
Western blot experiments
Protein samples (30 mg) from cell lysates were loaded on a NuPAGEH
NovexH 10% gel (Life Technologies) under reducing conditions,
transferred to a nitrocellulose membrane and incubated overnight at
4 C˚ under agitation with anti-human CX3CL1 primary antibody, which
recognizes the CD domain (AF365, 1/500 dilution, R&D Systems
Europe, Lille, France). Immune complexes were visualized with
secondary peroxidase-conjugated antibodies, using a chemiluminescent
kit (GE Healthcare Europe, Saclay, France).
Fluorescence recovery after photobleaching (FRAP) experiments
Cells were seeded into four wells borosilicate slide Labtek II chamber
(Nunc, Dutscher, Brumath, France) 48 h before the experiments and
transfected (HEK293, COS7, and CHOldlD) or stimulated (HUVEC) 24 h
before the FRAP experiments. Stimulated HUVEC cells expressing
CX3CL1 were incubated with fluorescein-labeled anti-CX3CL1
polyclonal antibody (IC365F from R&D Systems) 1 h before the
experiments. Confocal imaging was performed on live cells with a Leica
SP5 microscope using a 488-nm laser beam for EYFP or FITC excitation
and the filter sets supplied by the manufacturer. The cells were maintained at
37 C˚ on the microscope stage. In the FRAP experiments, the measurements
were performed using a Leica 636dry objective. Two identical regions of
interest (ROI) were monitored: one was photobleached during three scans
with the 488 nm laser beam at full power, and the other was used to monitor
the concomitant effects of intrinsic photobleaching. The pre- and post-bleach
images were monitored at low laser intensity (10 to 15% of full power). The
fluorescence in the ROIs was quantified using the LASAF Leica software.
The analysis of the curve of the resulting fluorescence recovery as a function
of time yielded the recovery times that were used to obtain the diffusion
coefficients of the diffusing species. The diffusion coefficient is equal to
D~r2

4t
where ‘‘r’’ is the radius of the circular beam and ‘‘t’’ is the time constant
obtained from the fit of the curve (Soumpasis, 1983). In our experiments,
each cell was bleached over three different circular regions with diameters of
3, 4, or 5 mm. The characteristic recovery times (t) and fluorescence
recovery plateau (Fp) were calculated by fitting the fluorescence recovery
curves as previously described (Soumpasis, 1983; Braeckmans et al., 2003).
The mobile fraction was calculated as the ratio of Fp to the initial
fluorescence level (F0).
Evaluation of membrane expression of EYFP chimera proteins by
confocal microscopy
The membrane expression of different EYFP-CX3CL1 chimeras was
evaluated as previously described (Janecki et al., 2000). Briefly, the
intensity of EYFP fluorescence corresponding to the plasma membrane
was calculated by subtracting the value of the integrated fluorescence
intensity of EYFP within the cytoplasm from the total cellular
fluorescence intensity over at least five optical sections per cell. We
reported the mean of six cells for each condition.
Flow cytometry
The expression of different EYFP-CX3CL1 chimeras was analyzed by
flow cytometry using a FACSCalibur (Becton Dickinson, Le Pont de
Claix, France) and the FlowJo software (TreeStar, Ashland, OR, USA).
Transiently transfected COS-7 or CHOldlD cells were harvested from
culture flasks through treatment with cell dissociation buffer (Life
Technologies, Saint Aubin, France), washed in PBS, and centrifuged. The
cells were fixed in 0.5 mL of 4% paraformaldehyde in PBS for 10 min on
ice, washed with PBS/0.01% NaN3, and incubated at a density of 2.10
6
cells per mL with a phycoerythrin (PE)-conjugated anti-hCX3CL1
monoclonal antibody (R&D Systems) or a PE-conjugated IgG1 isotype
control (both at a concentration of 1.25 mg/mL Ab in PBS with 0.1%
BSA and 0.01% NaN3) for 1 h on ice. After two washes, the cells were
suspended in PBS containing 2% PFA.
Flow adhesion experiments
The laminar flow chamber adhesion assays were performed as previously
described (Daoudi et al., 2004). Briefly, Thermanox coverslips (Nunc,
Dutscher, Brumath, France) were cultured with adherent COS7 cells
transiently expressing the CX3CL1-EYFP, dgCX3CL1-EYFP, CX3CL1-
EYFP w/o the cytosolic domain (w/o cyto CX3CL1), or CX3CL1-EYFP
w/o the chemokine domain (w/o CD CX3CL1) mutants. The coverslip
was mounted in a chamber set on the stage of an inverted microscope
(TE300, Nikon) equipped with a phase-contrast 10 objective (Nikon, n.a.
0.25) and a cooled charge-coupled device camera (Sensicam, PCO,
Kelheim, Germany). The entire apparatus was maintained at 37 C˚ by a
thermostatic chamber (Life Imaging Services, Reinach, Switzerland).
CHO-CX3CR1 clone cells were suspended in PBS, incubated for 30 min
at 37 C˚ with 5 mM CellTrackerTM Orange CMTMR (Molecular Probes,
Life Technologies, CA, USA) for labeling, and resuspended in flow
buffer (HBSS supplemented with 1 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES, and 2 mg/ml bovine serum albumin) at a density of 106 cells/ml.
A syringe pump (PHD 2000; Harvard Apparatus, Les Ulis, France) was
used to drive 0.5 mL of the cell suspension through the chamber at a wall
shear stress of 1.5 dynes cm22. After a 10-min wash at 1.5 dynes cm22,
fluorescent images of six separate 0.5-mm2 fields were recorded to count
the adherent cells (excitation 450–500 nm, emission 510–560 nm,
dichroic filter Q505lp, Chroma, Brattleboro, VT, USA). The number of
CHO-CX3CR1 clone cells adhered to COS7 cells expressing CX3CL1 w/
o the chemokine domain was considered non-specific adhesion.
Cell-cell adhesion experiments using the dual pipette aspiration
technique
The dissociation force between the stable CX3CR1 clone and CHO and
COS7 cells transiently transfected with CX3CL1 was measured through
the dual pipette adhesion assay as previously described (Daoudi et al.,
2004). The assays were performed on the stage of a Leica inverted
microscope, which was positioned on an anti-vibration platform with a
digitally controlled thermostat and equipped with 106 and 636
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objectives. The incubation chamber consisted of the bottom of a 90-mm
Petri dish covered with the inverted bottom of a second dish of the same
size. All of the surfaces in contact with the cells were precoated with
BSA (5–10% in deionized water) for at least 30 min. To obtain glass
pipettes with an inner diameter from 3 to 4 mm, we pulled (with a Sutter
instrument, model P-2000), cut, and then fire-polished micropipettes with
a homemade microforge. Before the adhesion assay, the pipettes were
filled with sterile culture medium and preincubated in BSA. The cells
were manipulated with two micropipettes, each of which was held by its
own micromanipulator and connected to a combined hydraulic/pneumatic
system that provided the necessary control of the aspiration force applied
to the cells.
The protocol used in this study was adapted from the method described
by Chien and co-workers (Sung et al., 1986). Two cells, which were
collected by gentle aspiration onto the tip of each pipette (cell number 1
in pipette A, cell 2 in pipette B), were brought into contact through the
use of the micromanipulators and allowed to remain in contact for 5 min.
To separate the cells, the aspiration in pipette B was maintained at a level
that was sufficiently high to hold cell number 2 tightly, whereas the
aspiration in pipette A was increased in a stepwise manner, as measured
with a pressure sensor (Validyne: model DP103–38; ranging from 0 to
50,000 Pascal units). After each step, the pipettes were moved apart in an
effort to detach the adherent cells from one another. A pair pulled intact
from pipette A was moved back to the pipette orifice, the aspiration in the
pipette was increased, and another attempt was made to detach the cells
from each other. The cycle was repeated until the level of aspiration in
pipette A was sufficient to pull one cell from the other. The aspiration
employed in each cycle was monitored continuously. In most cases, the cell
deformation and contact area variation during the separation process were
very limited (less than 20% for the contact area), and the separation took
place suddenly, in less than a tenth of a second. The separation force (F) for
rigid structures can be deduced from the data. The values recorded for each
of the last two cycles in the series (Pn21 and Pn) were used to calculate F for
the pair tested using Eqn 1, where d is the internal diameter of pipette A.
F~p d=2ð Þ2 Pn{1zPnð Þ=2ð Þ ð1Þ
This relation assumes that the pressure inside the cell is the same as that in
the chamber, which is valid in our case because the tension of the cell is
essentially zero.
Statistical analysis
The results are expressed as the means 6 s.d. from at least 10
measurements. Ana analysis of variance (ANOVA) followed by Tukey
test was used to establish the levels of significance.
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Fig. S1. dgCX3CL1 aggregation determined by BRET. COS7 cells were
transiently transfected with luciferase-coupled and EYFP-coupled chimeras
of native CX3CL1 or dgCX3CL1 at different EYFP/luciferase ratios. The
control of unspecific BRET was performed with COS7 cells transiently
transfected with EYFP-coupled glycophorin A (GyPA-EYFP) and luciferase-
coupled CX3CL1. The BRET experiments were performed as previously
described (Hermand et al., 2008).
Fig. S2. Role of cytosolic domain in adhesion force. Dissociation force
between CX3CR1 stable CHO clone and COS7 cells transiently transfected
with CX3CL1-EYFP or with CX3CL1-EYFP w/o cyt. The cells expressing
CX3CL1-EYFP were pretreated or not with 500 nM Latrunculin B for 60 min
before the experiments. ** p , 0.01 compared with native CX3CL1-EYFP.
Fig. S3. Monodisperse character of the fluorescence recovery of
CX3CL1-EYFP in COS cells as analyzed by FRAPP. (A) Typical
fluorescence recovery curve by FRAPP using an interfringe of 4.4 mm. The
Y-axis shows the difference in intensity between the bright and dark fringes,
F(t). This difference reaches zero when the fluorescence is fully recovered.
The long time scale behaves as a single exponential and corresponds to the
recovery of the slow CX3CL1 population. The exponential fit (Fslow(t)) gives a
characteristic time corresponding to a diffusion coefficient of
Dslow50.005 mm2/s. (B) Plot of the contribution of the short timescale
behavior F(t)2Fslow(t), which also appears to be a single exponential with a
characteristic time that corresponds to a diffusion coefficient of
Dfast50.025 mm2/s. In this example, 67% of the CX3CL1 molecules in the
population are diffusing in the fast regime. The pure exponential behavior
indicates that the diffusive objects (bundles of CX3CL1) are essentially
monodisperse in size.
RESEARCH ARTICLE Biology Open (2014) 000, 1–10 doi:10.1242/bio.20149845
S1
B
io
lo
g
y
O
p
e
n
Fig. S4. Membrane localization of CX3CL1 and dgCX3CL1 expressed in
CHOldlD cells under low serum conditions (0.1% FCS). (A)
Representative images of CHOldlD cell expressing dgCX3CL1 (top panel)
and native CX3CL1 (bottom panel). Images were taken with a Leica SP5
confocal microscope (636dry objective). The bars represent 10 mm. (B) Flow
cytometry signal ratio between anti-CX3CL1 PE-conjugated antibody
fluorescence and EYFP fluorescence. CHOldlD cells expressing dgCX3CL1-
EYFP or native CX3CL1-EYFP were cultured under low serum condition and
labelled using anti-CX3CL1 PE-conjugated antibody. Fluorescence signal
was analyzed by flow cytometry.
Table S1. Characteristics of the lateral diffusion of CX3CL1 and CX3CR1 in various cell types measured through the
FRAPP technique
Cell type HEK293 HEK293 HEK293 TIRF HEK293 TIRF
Transfection and fluorescent staining Stable Stable Stable Stable
CX3CL1 CX3CR1 CX3CL1 CX3CR1
EYFP EYFP EYFP EYFP
D (mm2 s21) 0.017860.0033 0.055060.0076 0.025560.0028 0.054960.0035
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